Jeddi Ramzi, Ben Abdennebi Yosr, Allani Bassam, Belakhal Raihane, Aissaoui Lamia, Ben Abid Hela, Ali Zaher Belhadj, Meddeb Balkis
Service d'hématologie clinique, Hopital Aziza othmana, Tunis.
Tunis Med. 2007 Feb;85(2):174-6.
Tumor lysis syndrome is a potentially life threatening oncologic emergency that requires immediate medical intervention. The syndrome results from the destruction (or lysis) of a large number of rapidly dividing malignant cells spontaneously or during chemotherapy. The resulting metabolic abnormalities include hyperkaliemia, hyperuricemia, and hyperphosphatemia with secondary hypocalcemia, all of which put patients at risk for renal failure and alteration in cardiac function. The tumor lysis syndrome occurs most often in patients with large tumor burdens that are very sensitive to chemotherapy and radiotherapy, such as acute or chronic leukaemias with high leukocyte counts and high-grade lymphoma. The current standard management for tumor lysis syndrome consists of allopurinol or recombinant urate oxidase for high risk patient in conjunction with i.v. hydratation with or without alkalinization.
肿瘤溶解综合征是一种潜在的危及生命的肿瘤急症,需要立即进行医学干预。该综合征是由于大量快速分裂的恶性细胞在自发情况下或化疗期间被破坏(或溶解)所致。由此产生的代谢异常包括高钾血症、高尿酸血症和高磷血症伴继发性低钙血症,所有这些都会使患者面临肾衰竭和心功能改变的风险。肿瘤溶解综合征最常发生于肿瘤负荷大且对化疗和放疗非常敏感的患者,如白细胞计数高的急性或慢性白血病以及高级别淋巴瘤患者。目前肿瘤溶解综合征的标准治疗方法包括,对于高危患者使用别嘌醇或重组尿酸氧化酶,并联合静脉补液,可进行或不进行碱化处理。